Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis...

Full description

Bibliographic Details
Main Authors:	Mete Akin, Osman Cagin Buldukoglu, Haydar Adanir, Inci Suleymanlar, Dinc Dincer, Bulent Yildirim
Format:	Article
Language:	English
Published:	SAGE Publishing 2018-06-01
Series:	SAGE Open Medicine
Online Access:	https://doi.org/10.1177/2050312118781416

Similar Items

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant
by: Eric M. Yoshida, et al.
Published: (2017-05-01)

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant
by: Carmen Vinaixa, et al.
Published: (2017-05-01)

Ledipasvir and sofosbuvir for treatment of post- renal transplant hepatitis C infection: A case report withreview of literature
by: R Jha, et al.
Published: (2016-01-01)

Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
by: Chen-Hua Liu, et al.
Published: (2018-01-01)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
by: Jona T Stahmeyer, et al.
Published: (2017-01-01)

The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis
by: William Stokes, et al.
Published: (2017-01-01)

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
by: Jennifer S. Husson, MD, MPH, et al.
Published: (2017-12-01)

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis
by: Tingting Tao, et al.
Published: (2017-02-01)

Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)
by: Sergio Vicente-Sánchez, et al.
Published: (2017-03-01)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
by: Yang CHT, et al.
Published: (2018-07-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents
by: Jesús Quintero, et al.
Published: (2019-03-01)

Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
by: Narjes Shokatpour, et al.
Published: (2020-06-01)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report
by: Giovanni Covini, et al.
Published: (2018-10-01)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
by: Resmi Premji MD, et al.
Published: (2015-12-01)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
by: Peter Buggisch, et al.
Published: (2019-01-01)

Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir
by: Chen-Hua Liu
Published: (2017-05-01)

Ledipasvir/sofosbuvir induced nephrotic syndrome: A challenging case of Hepatitis C management
by: Zaver, Himesh, et al.
Published: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
by: Naylor PH, et al.
Published: (2017-03-01)

Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
by: Shih-Jer Hsu, et al.
Published: (2020-03-01)

Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
by: Chantelli Iamblaudiot Razafindrazoto, et al.
Published: (2021-06-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
by: Patrick R. Brown, et al.
Published: (2018-10-01)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
by: Sachiko Omotani, et al.
Published: (2020-04-01)

The efficacy and safety of sofosbuvir/ledipasvir therapy in patients on long-term hemodialysis with hepatitis C virus infection
by: G Li Cavoli, et al.
Published: (2018-01-01)

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
by: Nkuize M, et al.
Published: (2016-06-01)

Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C
by: Jesús Quintero, et al.
Published: (2019-03-01)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
by: L. Tang, et al.
Published: (2018-01-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
by: Bashar Aqel, et al.
Published: (2018-09-01)

Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis
by: Xue Yang, et al.
Published: (2021-07-01)

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study
by: Catherine A Chappell, MD, et al.
Published: (2020-09-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)

Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C
by: Yuki Tahata, et al.
Published: (2018-08-01)

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis
by: Mohammad Saeid Rezaee-Zavareh, et al.
Published: (2017-03-01)

An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
by: Shyam Patel, et al.
Published: (2016-01-01)

Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report
by: Montserrat Fraga, et al.
Published: (2019-05-01)

Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
by: B Kirushnan, et al.
Published: (2016-01-01)

Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C
by: Aqsa Naseer
Published: (2017-12-01)

Cannot write session to /tmp/vufind_sessions/sess_humf18jv4ponck0lncba3lo17m